Evaluation of paraoxonase activity in patients with mixed connective tissue disease

Journal of Rheumatology

Volumn 35, Issue 2, 2008, Pages 237-243

  Bodolay, Edit ^a   Seres, Ildiko ^a   Szodoray, Peter ^a   Csípo, Istvan ^a   Jakab, Zsanett ^a   Vegh, Judit ^a   Szilagyi, Anna ^a   Szegedi, Gyula ^a,b   Paragh, Gyorgy ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Lipid levels; Mixed connective tissue disease; Paraoxonase; Vascular damage

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; CELL ANTIBODY; CHOLESTEROL; THROMBOMODULIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SPECTROPHOTOMETRY; TURBIDIMETRY;

ADULT; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; TRIGLYCERIDES;

EID: 39549112525     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Alves JD, Ames PRJ, Donohue S, et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002;46:2686-94.
2. van Leuven SI, Kastelein JJP, D'Cruz DP, Hughes GR, Stroes ES. Atherogenesis in rheumatology. Lupus 2006;15:117-21.
3. Goodson NJ, Wiles NJ, Lunt M, Barret EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-9.
4. Orem A, Deger O, Cimsit G, et al. Plasma lipoprotein(a) and its relationship with disease activity in patients with Bechet's disease. Eur J Clin Chem Clin Biochem 1995;33:473-8.
5. Cervera R, Khamashata MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1999;78:167-75.
6. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:338-46.
7. Jara LJ, Medina G, Vera-Lastra O, Amigo MC. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006;5:195-201.
8. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmun Rev 2002;1:348-53.
9. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
10. Chait A, Han CYH, Oram JF, Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389-93.
11. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972;52:148-59.
12. Hoffman RW, Greidinger EL. Mixed connective tissue disease. Curr Opin Rheumatol 2000;12:386-90.
13. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin N Am 2005;31:411-20.
14. Sullivan WD, Hurst DJ, Harmon CE, Esther JH. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine 1984;63:92-107.
15. Hassan BA, Ronnelid J, Gunnarsson I, Karisson G, Berg L, Lundberg I. Increased serum level of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease. J Autoimmun 1998;5:503-8.
16. Hassan BA, Gunnarsson I, Karisson G, Klareskog L, Forslid J, Lundberg IE. Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. Scand J Rheumatol 2001;5:282-9.
17. Bodolay E, Aleksza M, Antal-Szalmás P, et al. Serum cytokine levels, type 1 and intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 2002;29:2136-42.
18. Bodolay E, Csíp I, Gál I, et al. Antiendothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol 2004;22;409-15.
19. Jang JJ, Olin JW, Fuster V. A teenager with mixed connective tissue disease presenting with an acute coronary syndrome. Vasc Med 2004;9:31-4.
20. Kanazawa M, Wada Y, Ohno T, et al. Mixed connective tissue disease associated with anti-neutrophil cytoplasmic antibodies against proteinase-3 and systemic atherosclerosis: a case report. Clin Rheumatol 2004;23:456-59.
21. Alarcon-Segovia DA, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Excerpta Medica; 1987:33-40.
22. Paragh G, Seres I, Harangi M, et al. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab 2003;29:613-8.
23. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiological consequences. Nutr Metab Cardiovasc Dis 2006;16:371-86.
24. Getz GS, Reardon CA. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 2004;15:261-7.
25. Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidaemia. Nephron 1998;80:166-70.
26. Tsuzura S, Ikeda Y, Suehiro T, et al. Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human paraoxonase in patients with type 2 diabetes. Metabolism 2004;53:297-02.
27. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2003;39:59-6.
28. Dinu AR, Merril JT, Shen C, Antonov IV, Myones BL, Lahita RG. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998;7:355-60.
29. Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K, Tonozuka N, Hayashi T, Umeda M. Anti-apolipoprotein A-I autoantibody characterisation of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 2001;28:990-5.
30. Tanimoto N, Kumon Y, Suehiro T, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003;72:2877-85.
31. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and their potential to influence lipid peroxidation. Atherosclerosis 1995;115:243-53.
32. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalisation of paraoxonase, clusterin and apolipoprotein A1 in the human artery wall with progress of atherosclerosis. Arterioscler Thromb Vase Biol 1997;17:1233-8.
33. Sasaki N, Kurose A, Inoue H, Sawai T. A possible role of anti-endothelial cell antibody in the sera of MCTD patients on pulmonary vascular damage relating to pulmonary hypertension. Ryumachi 2002;42:885-94.
34. Nishimaki T, Aotsuka S, Kondo H. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999;26:2357-62.
35. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: A case-cohort study. Lancet 1999;353:1729-34.
36. Wu KK. Soluble thrombomodulin and coronary heart disease. Curr Opin Lipidol 2003;14:373-5.
37. Pasdar A, Ross-Adams H, Cumming A, et al. Paraoxonase gene polymorphism and haplotype analysis in a stroke population. BMC Med Genet 2006;7:28.
38. Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphism, oxidative stress, and diseases. J Mol Med 2003;81:766-9.
39. Association between PON1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications 2006;20:322-8.
40. Doria A, Sarzi-Puttini P, Shoenfeld Y. 2nd Conference on Heart, Rheumatism and Autoimmunity, Pescara, Italy, May 19-20, 2005. Autoimmun Rev 2006;5:55-63.
41. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high density lipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74.